Product
TAK-279
11 clinical trials
7 indications
Indication
Healthy Control ParticipantsIndication
PsoriasisIndication
ulcerative colitisIndication
Crohn's diseaseIndication
Liver ImpairmentIndication
Renal ImpairmentIndication
Generalized Pustular PsoriasisClinical trial
A Phase 1, 3-Part, Open-label, Drug-Drug Interaction Study to Evaluate the Effect of a Moderate CYP3A4 Inhibitor, and of Strong and Moderate CYP3A4 Inducers on the Pharmacokinetics of TAK-279 in Healthy SubjectsStatus: Completed, Estimated PCD: 2023-12-18
Clinical trial
A Phase 3, Randomized, Multicenter, Double-Blind, Placebo- and Active Comparator-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-279 in Subjects With Moderate-to-Severe Plaque PsoriasisStatus: Recruiting, Estimated PCD: 2025-08-15
Clinical trial
A Phase 3, Randomized, Multicenter, Double-Blind, Placebo- and Active Comparator-Controlled Study With a Randomized Withdrawal and Retreatment Period to Evaluate the Efficacy, Safety, and Tolerability of TAK-279 in Subjects With Moderate-to-Severe Plaque PsoriasisStatus: Recruiting, Estimated PCD: 2025-07-19
Clinical trial
A Phase 2, Multicenter, Randomized, Placebo-Controlled, Double-Blind Induction Study to Evaluate the Efficacy and Safety of Oral TAK-279 in Subjects With Moderately to Severely Active Ulcerative ColitisStatus: Recruiting, Estimated PCD: 2026-09-30
Clinical trial
A Phase 1, Randomized, Double-Blinded, Placebo-Controlled, Single and Multiple Oral Doses Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of TAK-279 in Healthy Chinese SubjectsStatus: Not yet recruiting, Estimated PCD: 2024-12-12
Clinical trial
A Phase 2b, Multicenter, Randomized, Double-Blind Induction, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of Oral TAK-279 in Subjects With Moderately to Severely Active Crohn's DiseaseStatus: Recruiting, Estimated PCD: 2026-09-18
Clinical trial
An Open-Label, Phase 1 Study to Compare Pharmacokinetics, Safety, and Tolerability of a Single Oral Dose of TAK-279 in Subjects With or Without Hepatic ImpairmentStatus: Recruiting, Estimated PCD: 2024-08-08
Clinical trial
An Open-Label, Phase 1 Study to Compare Pharmacokinetics, Safety, and Tolerability of a Single Oral Dose of TAK-279 in Subjects With or Without Renal ImpairmentStatus: Recruiting, Estimated PCD: 2025-01-13
Clinical trial
A Phase 1, Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel Design Thorough QT Study With Nested Crossover to Investigate the Potential of TAK-279 to Prolong the QTc Interval in Adult Healthy SubjectsStatus: Recruiting, Estimated PCD: 2024-06-25
Clinical trial
A Phase 3, Open-Label, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-279 in Adult Subjects With Generalized Pustular Psoriasis or Erythrodermic PsoriasisStatus: Recruiting, Estimated PCD: 2025-06-30
Clinical trial
A Phase 1, Open-Label, Drug-Drug Interaction Study to Assess the Effect of TAK-279 on the Pharmacokinetics of a Sensitive CYP3A4 Substrate and a Sensitive CYP2C8 Substrate in Healthy SubjectsStatus: Completed, Estimated PCD: 2024-05-03